Jiangsu Alphamab Biopharmaceuticals Co., Ltd. Enters into Research and Collaboration Agreement with Arrivent Biopharma, Inc
June 05, 2024 at 05:00 am
Share
The board (the "Board") of directors (the "Directors") of the Company announced that on June 5, 2024, Jiangsu Alphamab Biopharmaceuticals Co., Ltd. ("Alphamab"), entered into a research and collaboration agreement (the
"Collaboration Agreement") with ArriVent BioPharma, Inc. According to the terms of the Collaboration Agreement, Alphamab and ArriVent will collaborate to use Alphamab ' s proprietary linker-payload (Alphatecan) and glycan-conjugation platforms to discover and develop novel antibody drug conjugates (" ADC "). Alphamab will retain the rights to develop and commercialize the related ADC products (the "ADC Products") under the Collaboration Agreement, in mainland China, Hong Kong Special Administrative Region, Macau Special Administrative Region and Taiwan Region (collectively, the "Greater China Region"). ArriVent will have exclusive rights to develop and commercialize the ADC Products in the field of oncology in countries and regions outside of the Greater China Region and will be responsible for and bear the cost of the corresponding development of the ADC Products. According to the Collaboration Agreement, Alphamab is entitled to receive a one-time, non-refundable upfront payment and potential milestone payments based on the achievement of certain regulatory, development, and sales milestones of up to US$615.5 million in aggregate for the programs. In addition, Alphamab is also entitled to receive tiered sales royalties from ArriVent for each ADC Product.
ArriVent Biopharma, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in the identification, development and commercialization of differentiated medicines to address the unmet medical needs of patients with cancers. Its lead development candidate, Furmonertinib, and advance a pipeline of novel therapeutics, such as antibody drug conjugates, through approval and commercialization in patients suffering from cancer, with an initial focus on solid tumors. Furmonertinib is an oral, highly brain-penetrant, active mutation-selective EGFR inhibitor that targets both classical (exon 19 deletion and L858R) and uncommon EGFR mutations, including exon 20 insertion mutations, as well as HER2 exon 20 insertion mutations. Furmonertinib is an investigational, novel, EGFR mutant-selective tyrosine kinase inhibitor that is developing for the treatment of NSCLC patients across a set of EGFR mutations. It is also focused on development and commercialization of the ARR-002 program.
ARRIVENT BIOPHARMA, INC. 
